Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients (HF-ACZ)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01377987|
Recruitment Status : Completed
First Posted : June 22, 2011
Results First Posted : June 13, 2018
Last Update Posted : June 13, 2018
The ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment.
The study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the most severe ventilatory control instability (strongest chemoreflex response to carbon dioxide; highest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function.
|Condition or disease||Intervention/treatment||Phase|
|Heart Failures||Drug: Acetazolamide Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Physiological Study to Predict Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||December 2016|
4 mg/kg, once daily before bed, for 7 days
Other Name: Diamox
|Placebo Comparator: Sugar pill||
4 mg/kg, once daily before bed, for 7 days
- The Severity of Sleep Disordered Breathing (Apnea-hypopnea Index, AHI) [ Time Frame: 1 week ]The frequency of apneas and hypopneas (apnea-hypopnea index) was assessed. The primary measure was the value for non-REM supine sleep. A higher value indicates more severe sleep apnea. A value above 15 indicates the presence of moderate-to-severe sleep apnea.
- Ventilatory Chemoreflex Sensitivity, "Loop Gain" Using Carbon Dioxide Pulses [ Time Frame: 1 week ]
Chemoreflex "loop gain" was assessed according to Sands SA et al AJRCCM 2017 Jan 15;195(2):237-246. Loop gain is a unitless ratio measure that describes the magnitude of the increase in ventilation that occurs in response to a prior reduction in ventilation ("disturbance") and has units of L/min per L/min. A larger value indicates a more sensitive and unstable control system predisposing to oscillatory breathing. Loop gain was measured on the time scale of 1 min (i.e. response to a 1 cycle/min sinusoidal disturbance, referred to as "LG1"). The procedure involved brief administration of 7% carbon dioxide in air for 0.5 min ("pulses"); tests were repeated every 3 min for 30 min while measuring ventilation and carbon dioxide levels at the nose with patients awake and supine.
measured using 0.5 min pulses of carbon dioxide.
- Sympathetic Activity (Urinary Norepinephrine) [ Time Frame: 1 week ]Urinary norepinephrine levels overnight
- Left-atrial Volume [ Time Frame: 1 week ]Left-atrial volume index, echocardiography, bi-plane method. Lower values were considered a favorable outcome. We considered values ≤28 mL/m^2 to indicate normal left atrial volume. Values indicating graded left atrial enlargement were described as follows: mild (29-33 mL/m^2), moderate (34-39 mL/m^2), severe (≥40 mL/m^2).
- Brain Natriuretic Peptide (NT-proBNP) [ Time Frame: 1 week ]Brain natriuretic peptide (NT-proBNP) in morning
- Pittsburgh Sleep Quality Index [ Time Frame: 1 week ]Pittsburgh Sleep Quality Index is a measure of self-reported sleep quality containing 19 questions that make up 7 component scores that are added to provide a total score. Total scores range from 0-21 (units on a scale) with higher scores representing reduced sleep quality. A score of 5 or more is interpreted as reduced sleep quality. The total score is reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01377987
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Andrew Wellman, MD, PhD||Brigham and Women's Hospital|
|Principal Investigator:||Atul Malhotra, MD||Brigham and Women's Hospital|